Merck’s 15-valent pneumococcal conjugate vaccine receives Breakthrough Therapy Designation

Merck announced this week that V114, the company's investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. V114 is also under development for the ["]

The post Merck's 15-valent pneumococcal conjugate vaccine receives Breakthrough Therapy Designation appeared first on Outbreak News Today.